When to Resume ABVD Chemotherapy After Labour
ABVD chemotherapy should be resumed immediately after delivery once breastfeeding has been discontinued, as breastfeeding is contraindicated during chemotherapy. 1, 2
Key Timing Considerations
Immediate Postpartum Period
The evidence from acute promyelocytic leukemia guidelines, which addresses chemotherapy in the peripartum period, clearly states that breastfeeding is contraindicated if chemotherapy is needed after delivery 1. This principle applies directly to ABVD chemotherapy for Hodgkin lymphoma.
Once the decision is made not to breastfeed (or breastfeeding has been stopped), chemotherapy can be resumed without delay. The mode of delivery (vaginal vs. cesarean) does not impact the timing of chemotherapy resumption, though the patient must be medically stable and recovered from the delivery itself.
Practical Algorithm for Resumption
- Ensure breastfeeding cessation: Patient must commit to not breastfeeding before chemotherapy resumes
- Assess maternal recovery: Patient should be hemodynamically stable, without active bleeding complications, and able to tolerate chemotherapy
- Resume ABVD: Typically within 1-2 weeks postpartum once maternal recovery is adequate
Evidence on Chemotherapy Components and Breastfeeding
While limited data exist on ABVD specifically in breast milk, research on individual chemotherapy agents demonstrates significant drug presence in breast milk. A 2022 study found that doxorubicin (a component of ABVD) requires several days of milk discarding to reach safe cumulative relative infant doses 3. However, given the continuous nature of ABVD cycles and the presence of multiple cytotoxic agents, complete avoidance of breastfeeding is the only safe approach rather than attempting to "pump and dump."
Important Caveats
- Do not delay necessary chemotherapy: The goal remains curative treatment of Hodgkin lymphoma. Maternal survival takes priority, and chemotherapy should not be unnecessarily delayed postpartum
- Multidisciplinary coordination: Involve hematology/oncology, obstetrics, and neonatology in the timing decision 1
- Consider cycle timing: If delivery occurred mid-cycle, resume at the appropriate point in the treatment schedule rather than restarting the entire cycle
- Monitor for postpartum complications: Ensure no active infection, adequate blood counts, and resolution of any delivery-related complications before resuming myelosuppressive chemotherapy
Mode of Delivery Considerations
The guidelines suggest that vaginal delivery may be preferred when feasible due to reduced bleeding risk 2, but this does not affect chemotherapy resumption timing. Whether delivered vaginally or by cesarean section, the key determinant is maternal medical stability and breastfeeding cessation.
Physiologic Recovery
While physiologic changes of pregnancy (hepatic metabolism, renal clearance, plasma volume) take several weeks to fully normalize postpartum 4, this should not delay resumption of chemotherapy when treating active malignancy. The priority is disease control and maternal survival.